HbA1c is a Predictive Factor of Severe Coronary Stenosis and Major Cardiovascular Adverse Events in Both Type 2 Diabetic and Coronary Heart Disease
Article Sidebar
Main Article Content
Abstract
Background: Hemoglobin A1c (HbA1c) is an established marker of long-term glycemic control in diabetic patients. Recent evidence suggests that elevated HbA1c levels may serve as an independent risk factor for severe coronary stenosis and major cardiovascular adverse events (MACE) in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD).
Objective: This study aimed to investigate the predictive role of HbA1c in determining the risk of severe coronary stenosis and MACE in patients with T2DM and CHD.
Methods: A prospective cohort study was conducted on 220 patients with T2DM and CHD at the Cardiology Department of PIMS, Islamabad, from March 1, 2024, to July 31, 2024. Baseline HbA1c levels were measured, and patients were followed for 12 months. Coronary angiography assessed the severity of coronary stenosis (≥70% lumen reduction), and MACE occurrences were documented. Logistic regression and Cox proportional hazards models were used to analyze the data.
Results: The study found that patients with HbA1c ≥7.5% had a higher prevalence of severe coronary stenosis (61.8% vs. 30.9%, p<0.001) and increased risk of MACE (HR: 2.1, 95% CI: 1.2-3.5, p=0.005).
Conclusion: Elevated HbA1c is a significant predictor of severe coronary stenosis and MACE in T2DM patients with CHD, emphasizing the importance of stringent glycemic control.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
World Health Organization. Cardiovascular Diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes. Diabetes Care. 2019;42(Suppl 1).
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407-18.
Preis SR, Hwang SJ, Coady S, et al. Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728-35.
Marso SP, Hiatt WR. Antiplatelet Therapy in Diabetes Mellitus. Prog Cardiovasc Dis. 2006;49(4):292-300.
Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104.
Khaw KT, Wareham N, Bingham S, et al. Association of Hemoglobin A1c With Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med. 2004;141(6):413-20.
Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical States of Glucose Intolerance and Risk of Death in the U.S. Diabetes Care. 2002;24(3):447-53.
Van Der Meer RW, Lamb HJ, De Jong HW, et al. Persistent Cardiac Dysfunction Despite Intensive Glycemic Control in Patients With Type 1 Diabetes. J Clin Endocrinol Metab. 2007;92(10):3704-9.
Vogel B, Claessen BE, Arnold SV, et al. ST-Segment Elevation Myocardial Infarction. Nat Rev Dis Primers. 2018;4:20.
Keeley EC, Boura JA, Grines CL. Primary Angioplasty Versus Intravenous Thrombolytic Therapy for Acute Myocardial Infarction: A Quantitative Review of 23 Randomised Trials. Lancet. 2003;361(9351):13-20.
Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD. Eur Heart J. 2013;34(39):3035-87.
Stratton IM, Adler AI, Neil HA, et al. Association of Glycaemia With Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ. 2000;321(7258):405-12.
Selvin E, Steffes MW, Zhu H, et al. Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. N Engl J Med. 2010;362(9):800-11.
Patel A, MacMahon S, Chalmers J, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-72.
Gerstein HC, Miller ME, Byington RP, et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545-59.
Jiao X, Zhang Q, Peng P, Shen Y. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease. Diabetology & Metabolic Syndrome. 2023 Mar 20;15(1):50.